|

Personalized neoantigen tumor vaccine Clinical Trials

4 actively recruiting trials

Pipeline

Early 1: 4

Top Sponsors

  • Ruijin Hospital3
  • Shanghai Jiao Tong University School of Medicine1

Indications

  • Cancer4
  • Chemotherapy-intolerant1
  • Pancreatic Cancer Resectable1
  • Advanced Pancreatic Cancer1
  • Acute Myeloid Leukemia1

Other4 trials

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
Early 1
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
Early 1
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
Early 1
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.